$3.41
0.29% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US23284F1057
Symbol
CTMX

CytomX Therapeutics, Inc. Stock price

$3.41
+1.42 71.36% 1M
+2.78 439.98% 6M
+2.38 231.07% YTD
+2.29 204.46% 1Y
+2.00 141.84% 3Y
-3.40 49.93% 5Y
-9.81 74.21% 10Y
-9.49 73.57% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-0.01 0.29%
ISIN
US23284F1057
Symbol
CTMX
Industry

Key metrics

Basic
Market capitalization
$562.4m
Enterprise Value
$404.3m
Net debt
positive
Cash
$158.1m
Shares outstanding
164.9m
Valuation (TTM | estimate)
P/E
9.2 | 102.3
P/S
4.0 | 5.9
EV/Sales
2.9 | 4.3
EV/FCF
negative
P/B
4.7
Financial Health
Equity Ratio
-0.4%
Return on Equity
-6,988.8%
ROCE
31.8%
ROIC
-784.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$141.1m | $95.1m
EBITDA
$44.7m | $22.4m
EBIT
$43.1m | $4.7m
Net Income
$48.0m | $5.5m
Free Cash Flow
$-77.7m
Growth (TTM | estimate)
Revenue
18.0% | -31.2%
EBITDA
486.6% | -16.1%
EBIT
654.1% | -81.1%
Net Income
333.0% | -82.7%
Free Cash Flow
10.0%
Margin (TTM | estimate)
Gross
-
EBITDA
31.7% | 23.6%
EBIT
30.6%
Net
34.0% | 5.8%
Free Cash Flow
-55.1%
More
EPS
$0.4
FCF per Share
$-0.5
Short interest
19.7%
Employees
120
Rev per Employee
$1.2m
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a CytomX Therapeutics, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
141 141
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
4% 4%
21%
- Research and Development Expense 68 68
18% 18%
48%
45 45
487% 487%
32%
- Depreciation and Amortization 1.57 1.57
17% 17%
1%
EBIT (Operating Income) EBIT 43 43
654% 654%
31%
Net Profit 48 48
333% 333%
34%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Positive
Seeking Alpha
2 days ago
CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response rate given the late stage of the colorectal cancer patients enrolled in the study. CTMX finished Q2'25 with $158.1M in cash, which it expects to last into Q2'27.
Positive
Seeking Alpha
4 days ago
Tariff fears have returned to markets just as stocks passed the six-month mark from April's "Liberation Day" bottom. In this article, I look back to find the highest performing stocks since the big April correction and pull out the top five that still have Strong Quant Buy ratings. Each of these top five Strong Buy Quant stocks delivered exceptional six-month gains, supported by robust earnings...
Neutral
Seeking Alpha
10 days ago
CytomX Therapeutics pivots to focus on CX-2051 for metastatic colorectal cancer after terminating prior clinical candidates and restructuring operations. CX-2051 shows promising early Phase 1 efficacy (28% ORR, up to 43% at highest dose) but presents notable GI toxicity risks requiring close monitoring. Financially, CTMX is well-capitalized with $158.1 million in cash, providing a cash runway i...
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 120
Founded 2010
Website cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today